ATE188486T1 - Modifizierte polypeptide mit erhoehter biologischer aktivitaet - Google Patents

Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Info

Publication number
ATE188486T1
ATE188486T1 AT95912917T AT95912917T ATE188486T1 AT E188486 T1 ATE188486 T1 AT E188486T1 AT 95912917 T AT95912917 T AT 95912917T AT 95912917 T AT95912917 T AT 95912917T AT E188486 T1 ATE188486 T1 AT E188486T1
Authority
AT
Austria
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Application number
AT95912917T
Other languages
English (en)
Inventor
Arthur J Sytokowski
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Application granted granted Critical
Publication of ATE188486T1 publication Critical patent/ATE188486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95912917T 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet ATE188486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity
PCT/US1995/003242 WO1995025746A1 (en) 1994-03-22 1995-03-15 Modified polypeptides with increased biological activity

Publications (1)

Publication Number Publication Date
ATE188486T1 true ATE188486T1 (de) 2000-01-15

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912917T ATE188486T1 (de) 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Country Status (9)

Country Link
US (1) US5580853A (de)
EP (1) EP0751959B1 (de)
AT (1) ATE188486T1 (de)
DE (1) DE69514342T2 (de)
DK (1) DK0751959T3 (de)
ES (1) ES2143620T3 (de)
GR (1) GR3033146T3 (de)
PT (1) PT751959E (de)
WO (1) WO1995025746A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1997035561A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1623994A3 (de) * 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Schutz endogener therapeutisch aktiver Peptide vor Peptidaseaktivität durch Konjugation an Blutbestandteile
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
WO2002024899A2 (en) 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
JP2007500218A (ja) * 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
ES2395413T3 (es) * 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
EP1626983B8 (de) * 2003-05-12 2010-12-22 Affymax, Inc. Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
DE602004020610D1 (de) * 2003-05-12 2009-05-28 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
CA2564031A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006063055A2 (en) * 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
CA2593964A1 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP5165387B2 (ja) * 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP3539572A1 (de) * 2005-08-24 2019-09-18 ImmunoGen, Inc. Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP2120998B1 (de) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2437790B1 (de) 2009-06-03 2019-02-20 Immunogen, Inc. Konjugationsverfahren
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
EP2742064B1 (de) 2011-08-09 2016-07-27 UAB Profarma Derivate aus rekombinanten proteinen, homo-multimere des granulozyten-kolonie-stimulierenden faktors und verfahren zu ihrer herstellung
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
CN117658991A (zh) * 2023-12-05 2024-03-08 南昌大学 一种异型双功能交联剂及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
DE69514342T2 (de) 2000-11-30
GR3033146T3 (en) 2000-08-31
US5580853A (en) 1996-12-03
EP0751959A1 (de) 1997-01-08
WO1995025746A1 (en) 1995-09-28
EP0751959B1 (de) 2000-01-05
PT751959E (pt) 2000-06-30
DE69514342D1 (de) 2000-02-10
DK0751959T3 (da) 2000-06-26
ES2143620T3 (es) 2000-05-16

Similar Documents

Publication Publication Date Title
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
IT8812558A0 (it) Poltrona per abbronzatura
FI874819L (fi) Human rekombinant endotelcell vaextfaktor.
DE3582183D1 (de) Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
DK14890A (da) Peptider med t-hjaelpercelleaktivitet
DE3882593D1 (de) Polypeptid und dessen herstellung.
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
FI870633A7 (fi) Tuolin istuin.
DK96787A (da) Human vaevs-plasminogenaktivator
DE3579148D1 (de) Polypeptid und polypeptidzusammensetzung.
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
DE68904336D1 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
DE69012958D1 (de) Fibrinolytisches Protein und Herstellungsweise dafür.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
KR890015933U (ko) 회전의자
DE69019581D1 (de) Polypeptid und dieses enthaltende antibaktierelle Präparate.
DK527287D0 (da) Polypeptid med interleukin-2-aktiviteter
DE68924022D1 (de) Protein mit hemmender Aktivität gegenüber menschlichem Plasmin.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
NO912072D0 (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee